H.C. Wainwright initiated coverage of Eupraxia Pharmaceuticals (EPRX) with a Buy rating and $12 price target Eupraxia has the potential for a best in class treatment for the “ever-growing” eosinophilic esophagitis market, the analyst tells investors in a research note. The firm says the company has shown the potential for an annual treatment of EP-104GI in this condition, which could grow to a 1M addressable patient market.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EPRX:
- Eupraxia Pharmaceuticals initiated with a Speculative Buy at Canaccord
- Eupraxia Pharmaceuticals Strengthens Governance with Board Elections and Strategic Approvals
- Eupraxia Pharmaceuticals to Host Virtual Event on EoE Treatment Study
- Eupraxia Pharmaceuticals reports Q1 net loss $6.8M vs. $6.2M last year
- Eupraxia Pharmaceuticals Reports Q1 2025 Financial Results